Use of 99m Tc‐sestamibi SPECT/CT for indeterminate renal tumours: a pilot diagnostic accuracy study
Authors:
Open Access
- 26 September 2022
- journal article
- editorial
- Published by Wiley in BJU International
- Vol. 130 (6) , 748-750
Abstract
No abstract availableFunding Information
- Royal College of Surgeons of England
This publication has 7 references indexed in Scilit:
- ‘Case of the Month’ from the Specialist Centre for Kidney Cancer, Royal Free London Hospital, UK: 99m Tc‐sestamibi SPECT‐CT to differentiate renal cell carcinoma from benign oncocytomaBJU International, 2021
- Diagnostic accuracy of 99mTc-sestamibi SPECT/CT for detecting renal oncocytomas and other benign renal lesions: a systematic review and meta-analysisAbdominal Radiology, 2020
- Association of Prevalence of Benign Pathologic Findings After Partial Nephrectomy With Preoperative Imaging Patterns in the United States From 2007 to 2014JAMA Surgery, 2019
- Correlation of 99mTc-sestamibi uptake in renal masses with mitochondrial content and multi-drug resistance pump expressionEJNMMI Research, 2017
- Renal Mass Biopsy: Always, Sometimes, or Never?European Urology, 2016
- Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour BiopsyEuropean Urology, 2016
- Nephron‐sparing surgery across a nation – outcomes from the British Association of Urological Surgeons 2012 national partial nephrectomy auditBJU International, 2015